Next Technology Holding 주식 (NASDAQ: NXTT)

에 대한 최신 뉴스 Next Technology Holding (NASDAQ:NXTT) 주식

Next Technology Holding

WeTrade Group

Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.

Next Technology Holding Inc. - Ordinary Shares

Next Technology Holding Inc

Lifeist Wellness Inc

Barclays analyst Theresa Chen maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Overweight and raises the price target from $31 to $32.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Kinder Morgan, Raises Price Target to $32

Barclays analyst Jeffrey Bernstein maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Overweight and raises the price target from $235 to $255.

Barclays Maintains Overweight on Darden Restaurants, Raises Price Target to $255

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) has outperformed the market over the past 5 years by 8.26% on an annualized basis producing an average annual return of 23.01%. Currently, Charles Schwab has a market capitalization of $162.53 billion. 
Buying $1000 In SCHW: If an investor had bought $1000 of SCHW stock 5 years ago, it would be worth $2,624.41 today based on a price of $89.45 for SCHW at the time of writing.
<h3>Charles Schwab's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750688129_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SCHW

Here's How Much You Would Have Made Owning Charles Schwab Stock In The Last 5 Years

Being a child star looks like an idyllic life, but the entertainment industry landscape is littered with former prodigies who grew up to struggle with financial hardship. Jami Gertz is not going to be one of them. That's partly because she's moved from the silver screen to the boardroom, where she is co-owner of the NBA's Atlanta Hawks.&nbsp;
The 59-year-old Gertz began her career in 1982 as a regular on the CBS show "Square Pegs," and also appeared in hit shows such as "Diff'rent Strokes" and "Family Ties." At the peak of her fame, Gertz played a leading role in vampire movie "The Lost Boys," which is widely hailed as a cult classic that became synonymous with the 80s generation.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Although "The Lost Boys" didn't propel Gertz into bona fide stardom, her work on the film is notable for another reason. While she was filming, Gertz's publicist introduced her to Tony Ressler, a banker for Drexel-Burnham Lambert. They became a couple and got married two years later.
During the early years of their marriage, Gertz continued acting and made appearances on "Ally McBeal," "Seinfeld," and "ER." Her last major role came as Dr. Melissa Reeves, the wife of Bill Paxton's character in the 1996 hit, "Twister." All the while, Ressler quietly built his reputation and fortune as a businessman. After the collapse of Drexel Burnham, he co-founded Apollo Global Management (NYSE:<a href="https://www.benzinga.com/quote/APO/news"> APO</a>) with Leon Black in 1990.
In 2015, the couple joined a group that included NBA Hall-of-Famer Grant Hill and purchased the Atlanta Hawks. Gertz recounted the tale in an interview with<a href="https://www.hollywoodreporter.com/business/business-news/how-jami-gertz-became-a-hollywood-nba-owner-1150556/"> The Hollywood Reporter</a>. &#8220;He [Ressler] has a little tiny desk in there, and he was taking calls in the closet,&#8221; Gertz said. &#8220;I was walking in and out of the closet. And he looked at me, and I looked at him, and he&#8217;s like, &#8216;Jami, are we going to do this?&#8217; I&#8217;m like, &#8216;I don&#8217;t know. I&#8217;m so scared.&#8217; And he&#8217;s like, &#8216;It would be so much fun.&#8217; And then we were jumping and screaming, &#8216;Oh my God — we just bought a basketball team!'&#8221;&nbsp;&nbsp;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
Gertz suddenly found herself in familiar territory: the spotlight. It wasn't Hollywood, but Ressler told the Hollywood Reporter his wife wasted no time in making her presence felt. Her official "coming out party" came when she represented the Hawks at the 2018 NBA Draft Lottery. Since then, Gertz's role with the Hawks has only increased, and she has thrown herself into the franchise.
Gertz and Ressler relocated to Atlanta in 2017, a move that caused her to put her acting career on hold. She has embraced her new role in Atlanta wholeheartedly.&nbsp; &#8220;It just seemed like a natural moment for me to take a break from acting,&#8221; she said. &#8220;It&#8217;s hard to even say it out loud, because I love what I do. It&#8217;s given me so many beautiful things in my life, taught me so many things about myself and the world around me.&#8221;
The team is much better off for Gertz's and Ressler's involvement. They were active participants in a $192 million renovation of the team&#8217;s stadium and in building a new 90,000 square foot practice facility. Gertz continues to put her stamp on the team by overseeing internal operations and focusing on making sure Hawks fans have a great time when they come to see the team. She sees it as an essential aspect of running a first-class NBA franchise.
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
"I bought tickets when I couldn't afford them. I worked hard enough where I could eventually become a season ticket holder," she told<a href="https://www.peachtreehoops.com/2020/8/19/21373731/jami-gertz-atlanta-hawks-nba-draft-lottery-2020-owner-interview-comments-tony-ressler"> Peachtreehoops.com</a>. "So, I'm coming from that fan experience, being in L.A., and seeing where there was great food, and then the food wasn't so good. All of those things. I care a ton about fan experience." Gertz is also thinking about the basketball side of the operation.
Ressler and his team handle the player transactions and long-term roster planning. However, he is just as committed to making Atlanta a championship-caliber<a href="https://www.benzinga.com/markets/24/02/36894409/franchises-in-the-united-states-three-keys-that-can-pave-the-way-to-business-success-in-the-american"> franchise</a> as Gertz is to creating a championship-caliber fan experience. It will take lots of hard work for Ressler and Gertz to make their <a href="https://www.benzinga.com/money/high-return-investments">investment</a> in the Atlanta Hawks pay off. So far, the on-court results have not been spectacular, but they are committed to Atlanta for the long haul.
Read Next: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Image: Shutterstock

All Grown Up-The 80's Child Star That's Now Co-Owner Of The NBA's Atlanta Hawks

Kingstone Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) (the "Company" or "Kingstone"), a Northeast regional property and casualty insurance holding company, today announced that its catastrophe reinsurance program for the period July 1, 2025 through June 30, 2026 has been finalized.
Meryl Golden, Chief Executive Officer at Kingstone, stated, "I am pleased to announce the successful completion of our 2025/2026 catastrophe reinsurance placement with favorable economic terms. In response to the significant growth in premium and exposure experienced in the past year, we increased our catastrophe reinsurance limit by 57%, or $160 million, to $440 million. The limit includes multi-year protection of $125 million sourced through the issuance of our first catastrophe bond, 1886 Re Ltd., as announced in May.

KINS

Kingstone Companies Finalizes Catastrophe Reinsurance Program For Period July 1, 2025 Through June 30, 2026; Increases Catastrophe Reinsurance Limit By 57%, Or $160M, To $440M

<a href="https://x.com/citronresearch/status/1937151090258333972?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/citronresearch/status/1937151090258333972?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

TDOC

Citron Research Posts On X "The Coiled Spring Wall The world's largest Telehealth platform now trades at just a $1.2B market cap — yet it quietly owns BetterHelp, the #1 brand in online therapy. Until now, BetterHelp operated as cash-pay only, and that meant 80% of potential users walked..."

Barclays analyst Pablo Monsivais maintains Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) with a Overweight and raises the price target from $34 to $37.

VTMX

Barclays Maintains Overweight on Corporacion Inmobiliaria, Raises Price Target to $37

Professional Capital Management CEO Anthony Pompliano has announced a $1 billion merger to launch ProCap Financial, a new <a href="https://www.benzinga.com/crypto">Bitcoin-focused financial services firm</a>.
The company, formed through a business combination with Columbus Circle Capital Corp. I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCM#NASDAQ">CCCM</a>), <a href="https://www.globenewswire.com/news-release/2025/06/23/3103348/0/en/Anthony-Pompliano-Strikes-1-Billion-Merger-to-Create-ProCap-Financial-Raises-Over-750M-in-Largest-Initial-Fundraise-in-History-for-Public-Bitcoin-Treasury-Company.html">plans </a>to hold up to $1 billion worth of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on its balance sheet.
The deal represents the largest initial fundraising in history for a publicly traded Bitcoin treasury company: $516.5 million in equity and $235 million in convertible notes.
Pompliano's venture secured backing from a mix of institutional and crypto-native investors including Magnetar Capital, Woodline Partners, Anson Funds, RK Capital, Off the Chain Capital, Parafi, Blockchain.com, Arrington Capital, BSQ Capital Partners, and FalconX. 
Morgan Creek Capital founder Mark Yusko, Main Street Ventures founder Jason Williams, Semler Scientific&#8217;s Eric Semler, renowned poker player Tony Guoga, and Eight Sleep CEO Matteo Franceschetti also participated.
ProCap Financial aims to actively acquire bitcoin and generate revenue from its holdings through diversified, risk-managed strategies. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46050168/investors-poured-billions-into-bitcoin-and-ethereum-even-as-iran-israel-tensions-escalated">Investors Poured Billions Into Bitcoin And Ethereum Even As Iran-Israel Tensions Escalated</a>
&#8220;The legacy financial system is being disrupted by Bitcoin. ProCap Financial represents our solution to the increasing demand for Bitcoin-native financial services among sophisticated investors,&#8221; Pompliano said.
The company plans to offer financial services that leverage its bitcoin treasury. It aims to position itself as a leader in the emerging market for digital asset-backed financial platforms.
ProCap's public listing will provide equity investors with immediate exposure to Bitcoin through the company's balance sheet structure.
The merger and initial capital raise signal growing institutional appetite for Bitcoin treasury companies, a trend previously accelerated by firms like MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Metaplanet, which have aggressively accumulated bitcoin to diversify their corporate treasuries.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46034531/this-record-credential-leak-could-change-how-you-log-in-forever-heres-why">This Record Credential Leak Could Change How You Log In Forever —Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CCCM

MSTR

Anthony Pompliano Unveils ProCap Financial With $1B Bitcoin Treasury After $750M Fundraise

Barclays analyst Terry Ma maintains Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) with a Overweight and raises the price target from $212 to $253.

Barclays Maintains Overweight on Capital One Finl, Raises Price Target to $253

Alpha Modus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>), a retail AI and data monetization company, today announced a major personal capital commitment from its CEO William Alessi to further support the company's rapid growth and operational plans for the remainder of 2025.
In a strong display of confidence, Mr. Alessi and his affiliated family trusts have recently completed the exchange of a substantial block of preferred shares into common stock, aligning long-term interests with shareholders. Now, he has personally committed up to $3 million in simple debt financing to ensure Alpha Modus remains well-capitalized and strategically focused through year-end while rejecting all third-party derivative financing offerings.
The company has applied to transfer its securities listing to the NASDAQ Capital Market and believes it will be compliant with all applicable Nasdaq listing standards upon transfer.
Alpha Modus intends to maintain a lean operational model with strategic financial support from its CEO, and it is focused on avoiding all variable rate financing in the future, which financing could compromise the value of its common shares.

AMOD

Alpha Modus Announces $3M Personal Capital Commitment From CEO William Alessi To Further Support Company's Growth And Operational Plans For Remainder Of 2025

Barclays analyst Ramsey El-Assal maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Overweight and lowers the price target from $390 to $360.

Barclays Maintains Overweight on Accenture, Lowers Price Target to $360

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
Six-Month Patient Follow-up Results Demonstrate that Sana's Transplanted Pancreatic Islet Cells Modified with its Hypoimmune (HIP) Technology are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient
Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT)
MRI Show Signals Consistent with Graft Survival Six Months after Transplantation
Study Continues to Evaluate Safety, Survival, and Function of Transplanted Cells
Data Shared at an Invited Presentation at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Today
Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose, with No Insulin and No Immunosuppression
SEATTLE, June 23, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>), a company focused on changing the possible for patients through engineered cells, today announced six-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The study is being conducted in partnership with Uppsala University Hospital. The results are consistent with and build upon the previously reported four-week and 12-week clinical results. Results of the study at six months after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase with a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. 12-week PET-MRI scanning also demonstrated islet cells at the transplant site, a forearm muscle. The study identified no safety issues, and the HIP-modified islet cells evaded immune responses.

SANA

Sana Biotechnology Announces 6-Month Follow-Up Results From First-In-Human Study Transplanting UP421, Allogeneic Primary Islet Cell Therapy Engineered With Sana's HIP Technology, Into Patient With T1D Without Any Immunosuppression

<a href="https://www.cnb.cz/en/economic-research/conferences-seminars-and-workshops/assessing-the-effectiveness-of-monetary-policy-during-and-after-the-covid-19-pandemic/">https://www.cnb.cz/en/economic-research/conferences-seminars-and-workshops/assessing-the-effectiveness-of-monetary-policy-during-and-after-the-covid-19-pandemic/</a>

Politics

Economics

Federal Reserve

Fed's Bowman Says Data Not Showing Much Impact From Trade Policy Shifts; Government Policy Changes Should Lower Inflation Risks; Tariffs Likely To Have Small Impact On Inflation; Progress On Trade Has Lowered Uncertainty Over Outlook; Current Middle East Strife Could Pressure Up Commodity Prices;  Labor Market Solid, But Signs Of Softness Emerging

Research also shows a reversal of the gender pay gap under VBC
agilon health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>), the trusted partner empowering physicians to transform health care in our communities, today announced the publication of new peer-reviewed data examining the impact of gender differences of primary care physicians (PCPs) on patient outcomes, healthcare utilization and revenue using different Medicare payment models, specifically value-based care (VBC) and fee-for-service (FFS). Research was published in the May 16, 2025, issue of the JAMA Health Forum.

agilon health Announces Publication Of New Peer-Reviewed Data Examining Impact Of Gender Differences Of PCPs On Patient Outcomes, Healthcare Utilization And Revenue Using Different Medicare Payment Models

Macro Economic Events

Fed's Bowman Says Open To Cutting Rates As Soon As July FOMC Meeting If Inflation Pressures Stay Contained; Should Put More Weight On Downside Risks To Job Market Going Forward; Says 'It Is Time To Consider Adjusting The Policy Rate'; Trade Policy Only Likely To Have 'Minimal Impacts' On Inflation

Whales with a lot of money to spend have taken a noticeably bullish stance on Meta Platforms.
Looking at options history for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 48% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $379,476 and 21, calls, for a total amount of $1,250,959.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $720.0 for Meta Platforms, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale activity within a strike price range from $5.0 to $720.0 in the last 30 days. 
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750687372_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$27.7</td>
<td>$27.15</td>
<td>$27.55</td>
<td>$660.00</td>
<td>$272.7K</td>
<td>409</td>
<td>230</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$61.6</td>
<td>$60.85</td>
<td>$60.85</td>
<td>$630.00</td>
<td>$91.2K</td>
<td>2.7K</td>
<td>16</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$16.7</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$685.00</td>
<td>$80.0K</td>
<td>262</td>
<td>56</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$32.95</td>
<td>$29.95</td>
<td>$31.75</td>
<td>$700.00</td>
<td>$79.3K</td>
<td>155</td>
<td>0</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$700.00</td>
<td>$76.8K</td>
<td>6.2K</td>
<td>1.7K</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
After a thorough review of the options trading surrounding Meta Platforms, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Meta Platforms</h3>
<ul>
<li>With a volume of 1,289,155, the price of META is down -0.04% at $682.09. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $737.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Meta Platforms, targeting a price of $775. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $676. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Meta Platforms with a target price of $664. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Meta Platforms with a target price of $765. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Meta Platforms, which currently sits at a price target of $807. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Meta Platforms, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Spotlight on Meta Platforms: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bearish move on Boeing. Our analysis of options history for Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $117,270, and 7 were calls, valued at $448,575.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $300.0 for Boeing over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Boeing's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Boeing's substantial trades, within a strike price spectrum from $200.0 to $300.0 over the preceding 30 days.
<h3>Boeing Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750687367_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$5.9</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$210.00</td>
<td>$118.0K</td>
<td>4.8K</td>
<td align="right">15</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.3</td>
<td>$9.1</td>
<td>$9.17</td>
<td>$210.00</td>
<td>$91.7K</td>
<td>10.3K</td>
<td align="right">102</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$3.7</td>
<td>$3.65</td>
<td>$3.7</td>
<td>$200.00</td>
<td>$74.0K</td>
<td>1.3K</td>
<td align="right">212</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$14.05</td>
<td>$12.6</td>
<td>$13.35</td>
<td>$200.00</td>
<td>$66.7K</td>
<td>1.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$220.00</td>
<td>$66.0K</td>
<td>3.1K</td>
<td align="right">215</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
After a thorough review of the options trading surrounding Boeing, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Boeing's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 485,690, the BA's price is up by 0.01%, now at $198.76. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>Professional Analyst Ratings for Boeing</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $230.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Boeing with a target price of $230. 
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $200. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Boeing with a target price of $250. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Buy, adjusting the price target to $212. 
&#x2A; An analyst from B of A Securities upgraded its action to Buy with a price target of $260. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on Boeing Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Walmart.
Looking at options history for Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 13% of the investors opened trades with bullish expectations and 80% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $650,072 and 6, calls, for a total amount of $336,674.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $95.0 to $150.0 for Walmart over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Walmart's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walmart's whale activity within a strike price range from $95.0 to $150.0 in the last 30 days. 
<h3>Walmart Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750687362_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$10.1</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$100.00</td>
<td>$161.0K</td>
<td>1.8K</td>
<td align="right">162</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$6.0</td>
<td>$95.00</td>
<td>$120.0K</td>
<td>3.1K</td>
<td align="right">230</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.4</td>
<td>$6.25</td>
<td>$6.45</td>
<td>$100.00</td>
<td>$96.7K</td>
<td>2.4K</td>
<td align="right">352</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$100.00</td>
<td>$79.3K</td>
<td>2.4K</td>
<td align="right">202</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.85</td>
<td>$9.7</td>
<td>$9.85</td>
<td>$105.00</td>
<td>$75.8K</td>
<td>580</td>
<td align="right">88</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart is a leading retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $460 billion in domestic namesake sales in fiscal 2025, with Sam's Club contributing another $90 billion to the company's top line. Internationally, Walmart generated $120 billion in sales. The retailer serves around 270 million customers globally each week.
<h3>Current Position of Walmart</h3>
<ul>
<li>With a volume of 1,391,273, the price of WMT is up 0.23% at $96.34. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 59 days.</li>
</ul>
<h3>What Analysts Are Saying About Walmart</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $110.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Walmart, which currently sits at a price target of $110. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Walmart, maintaining a target price of $107. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Walmart with a target price of $103. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Walmart, targeting a price of $115. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Outperform rating on Walmart with a target price of $115. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Walmart, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding Walmart's Options Activity: What's the Big Picture?

Today MetLife announced that through a strategic collaboration with Nayya, it is expanding access of Upwise, MetLife's benefits experience platform, by making it available to employers through Workday Marketplace. This is another critical step in MetLife's strategy to extend market leadership and its commitment to address the benefits ‘confusion gap'1 prevalent in today's workforce. Since launching Upwise in 2024, the response has been outstanding, with a majority (64%) of employees stating the platform made their benefits decisions easier.2
Through this strategic collaboration, the benefits experience platform will be available by October 1, 2025, at no additional cost, to Workday Human Capital (HCM) and Workday Benefits customers via Workday Marketplace for employers which have in-force MetLife Accident, Hospital Indemnity, or Critical Illness insurance products or add one of these products to their benefits offering.

MetLife Collaborates With Nayya, Expanding Access Of Upwise Through Workday Marketplace

Analysts' ratings for WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated WAVE Life Sciences and provided 12-month price targets. The average target is $16.0, accompanied by a high estimate of $22.00 and a low estimate of $10.00. Observing a downward trend, the current average is 20.0% lower than the prior average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750687280_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Freeman</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to WAVE Life Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of WAVE Life Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of WAVE Life Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know WAVE Life Sciences Better</h2>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>Financial Insights: WAVE Life Sciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: WAVE Life Sciences's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -26.82%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: WAVE Life Sciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -510.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -24.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): WAVE Life Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where WAVE Life Sciences Stands With Analysts

Press Releases

Next Technology Holding Inc. Announces Receipt of Staff Determination Letters from Nasdaq.

Stocks Under $5 to Watch: KDLY, PRSO, NXTT, GRYP, YHC Lead Headlines with Bitcoin, AI, and Semiconductor Catalysts

GRYP

KDLY

NXTT

PRSO

Amplitude

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies

Cipher Mining

Sprinklr

Diginex

EverCommerce

Five9

Hut 8

Jamf Holding

Karooooo

Lightspeed Commerce Inc. Subordinate Voting Shares

Lightspeed Commerce

MeridianLink

NextNav

Opera Limited - American Depositary Shares

Opera

PagerDuty

Pagaya Technologies Ltd. - Class A Ordinary Shares

Pagaya Techs

Porch Group

LiveRamp Holdings

SEMrush Holdings, Inc. Class A Common Stock

SEMrush Hldgs

Sapiens International Corporation N.V. - Common Shares

Sapiens International

Sprout Social, Inc - Class A Common Stock

Sprout Social

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Comments

Next Technology Holding

뉴스

에 대한 최신 뉴스 Next Technology Holding (NASDAQ:NXTT) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌